Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakthrough RSV Immunization Study
NL-OMON58250Recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nirsevimab in respiratory syncytial virus disease (RSV) (4 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Serum RSV pre-F IgG levels. Started Feb 2026; status: recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON58250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58250.